BeyondSpring (BYSI) Other financing activities (2020 - 2026)

BeyondSpring (BYSI) posted Other financing activities of $280000.0 for Q1 2026, down 86.0% sequentially from $2.0 million in Q4 2024.

BeyondSpring (BYSI) Other financing activities (2020 - 2026) Analysis & Trends

BeyondSpring has reported Other financing activities for 3 years, with the latest figure at $280000.0 in Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to $280000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 14.0% YoY) and the FY2025 annual result came in at $2.7 million, down 86.4% from the prior year.
Other financing activities eased to $280000.0 in Q1 2026 per BYSI's latest filing, from $2.0 million in the prior quarter.
Over five years, Other financing activities peaked at $2.0 million in Q4 2024 and troughed at $280000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.77 Bn	131.91 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.74 Bn	78.75 Bn	3.93 Bn
3	Argenx Se	65.36 Bn	60.17 Bn	1.37 Bn
4	Moderna	59.60 Bn	54.47 Bn	52.00 Mn
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn
7	BioNTech SE	28.13 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.54 Bn	26.38 Bn	358.27 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-
10	BeyondSpring	29.77 Mn	29.77 Mn	-

Download Data